|
The Patient-Preferred HUMIRA® Pen
*
Prefilled syringe.
Study objective: To assess which method of delivery rheumatoid arthritis (RA) patients preferred—the HUMIRA prefilled syringe (PFS) or the new HUMIRA® Pen. Study design: A phase II, multicenter, open-label, sequential, single-arm study that included RA patients who had prior experience with the HUMIRA PFS. Patients (N=52) self-injected with HUMIRA PFS at Week 0 followed by injections of the HUMIRA® Pen at Weeks 2 and 4, completing questionnaires at all 3 time points. Patients rated their injection preferences for several attributes, including overall preference, ease of use, convenience, time to complete injection, and pain. Baseline demographics: Patients (N=52) were at least 18 years old, with an average age of 54 years. Patients had been using the HUMIRA PFS for an average of 15 months. 06G-64C-Q352-10 |
|
 |
||
HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older. HUMIRA can be used alone or in combination with methotrexate. HUMIRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in adult patients with psoriatic arthritis. HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy, and reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.
Please see Important Safety Information. Serious and sometimes fatal side effects have been reported with HUMIRA, including tuberculosis and other serious infections.
Please see full prescribing information.
Legal Notices/Privacy Policy. Copyright 2007, Abbott Laboratories, Abbott Park, Illinois, U.S.A. If you have any questions about Abbott's HUMIRA.com Web site that have not been answered click here. This Web site and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.